Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The sales force for a pharma company still represents one of the largest line items in the budget and is the most significant driver of sales relative to all other individual sales and marketing channels. Direct sales forces have the highest cost per contact relative to other channels (lowest efficiency) but have the greatest effect on sales per contact (highest effectiveness). So, making sure ...

Hope for a strong and quick recovery from the COVID-19 induced U.S. recession became more uncertain with the dramatic and historic decline in Q2 2020 U.S. GDP. There are also economic signs that a full economic recovery to pre-pandemic levels is still elusive. Continued economic uncertainty remains. Further, while the resurgence of COVID-19 cases seen in many states this past June, especially in ...

The upcoming November 2020 presidential and congressional elections represent a key event for the pharma industry. Current industry focus is on COVID-19, the effects from public policy mandates on pharma business operations, resulting in recessionary effects on market access and affordability, and the search for effective vaccines and treatments. Yet, a Democratic Party election sweep by winning ...

The pharmaceutical industry has stepped up in a big way in search of vaccines and effective treatments for COVID-19. One reference cited at least 250 drugs and 95 vaccines under investigation related to COVID-19. The coronavirus pandemic has clearly shown the societal value of having a pharmaceutical industry with a robust capability to develop new medicines and to operate in an economic system ...

This white paper investigates the research framework to model the expected effects of the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceutical utilization due to the economic effects of a deep and long recession. Four effects caused by a deep recession that will adversely affect the utilization of branded/biologic drugs, which, in turn, will cause a ...

The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmaceutical industry. The coronavirus pandemic also illustrates the need for companies to have empirical systems in place to act quickly to mitigate the effects of such events when they do occur. This white paper provides a ...

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what the future holds and what if any long-term global effects may result from this latest contagion. Therefore, this paper is about expanding on two themes that are of importance to the successful long-term operation of global ...

The importation of drugs from lower-priced countries, like Canada, was an idea brought up during the Clinton Administration as a way for consumers to bypass the high cost of prescription drugs in the US. The effect of allowing importation is essentially about the imposition of a foreign drug price control on the US market. The economic analysis of the adverse effects of price controls on R&D ...

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroeconomists who think they have mastered the science and art of counter-cyclical monetary and fiscal policies. The macroeconomic environment for pharma companies is an exogenous factor beyond the capability of any individual ...